Tech choice crucial in UK diabetes screening review
This article was originally published in Clinica
By the end of this year, the UK National Screening Committee should have decided whether or not to screen for type 2 diabetes - but the implications of detecting a potentially significant number of cases of lesser glucose intolerance could have a major bearing on the NSC's choice of diagnostic technology.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.